epigenetic silencing th1-type chemokines shapes tumour immunity immunotherapy 
epigenetic silencing including histone modifications dna methylation important tumorigenic mechanism1 however role cancer immunopathology immunotherapy poorly understood using human ovarian cancers model show enhancer zeste homologue ezh2-mediated histone h3 lysine trimethylation h3k27me3 dna methyltransferase dnmt1-mediated dna methylation repress tumour production t helper th1-type chemokines cxcl9 cxcl10 subsequently determine effector t-cell trafficking tumour microenvironment treatment epigenetic modulators removes repression increases effector t-cell tumour infiltration slows tumour progression improves therapeutic efficacy programmed death-ligand pd-l1; also known b7-h1 checkpoint blockade2- adoptive t-cell transfusion5 tumour-bearing mice moreover tumour ezh2 dnmt1 negatively associated tumour-infiltrating cd8+ t cells patient outcome thus epigenetic silencing th1-type chemokines novel immune-evasion mechanism tumours selective epigenetic reprogramming alters t-cell landscape6 cancer may enhance clinical efficacy cancer therapy 
